Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Oxidoreductase
Reexamination Certificate
2007-04-03
2007-04-03
Rao, Manjunath N. (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Oxidoreductase
C435S069100, C435S252300, C435S320100, C536S023200
Reexamination Certificate
active
10663377
ABSTRACT:
The invention provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 14, 16, 18, 20, 22 or 24. The invention also provides an isolated polypeptide containing a) an amino acid sequence having at least 50% amino acid identity with SEQ ID NO: 10, and b) an amino acid sequence selected from SEQ ID NOS: 14, 16, 18, 20, 22, or 24; or a conservative variant thereof. The invention further provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 2, 4, 6, or 8. The invention also provides a method for identifying a compound that modulates a COX-1 variant by contacting an isolated COX-1 variant or a COX-1 variant over-expressed in a genetically engineered cell with a compound and determining the level of an indicator which correlates with modulation of a COX-1 variant, where an alteration in the level of the indicator as compared to a control level indicates that the compound is a compound that modulates the COX-1 variant.
REFERENCES:
patent: 2004/0172684 (2004-09-01), Kovalic et al.
Carelli et al., “Optic nerve degeneration and mitochondrial dysfunction: Genetic and acquired optic neuropathies,”Neurochem. Int. 40:573-584 (2002).
Chandrasekharan et al., “COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression,”Proc. Natl. Acad. Sci USA99:13926-13931 (2002).
“Chemiluminescent Cyclooxygenase Activity Kit: Catalog No. 907-003,” Assay Designs, Inc. 1-12.
“Cox Activity Assay: Catalog No. 760151,” Cayman Chemical 1-8.
“Cox (human) inhibitor screening assay: Catalog No. CM51061,” IBL Immuno-Biological Laboratories 1-8.
Crofford, “COX-1 and COX-2 tissue expression: Implications and predictions,”J. Rheumatol. 24:15-19 (1997).
“Cyclooxygenase Activity Kit: Catalog No. EKS-320” Stressgen Biotechnologies 1-10.
Dewitt and Smith, “Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence,”Proc. Natl. Acad. Sci. USA85:1412-1416 (1988).
Dewitt et al., “The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases,”J. Biol. Chem. 265:5192-5198 (1990).
Diaz et al., “Alternative splicing of human prostaglandin G/H synthase mRNA and evidence of differential regulation of the resulting transcripts by transforming growth factor beta 1, interleukin 1 beta, and tumor necrosis factor alpha,”J. Biol. Chem267:10816-10822 (1992).
Droge et al., Alternative Splicing of Cyclooxygenase-1 mRNA in the Human Iris,Ophthalmic. Res. 35:160-163 (2003).
Dubois et al., “Cyclooxygenase in biology and disease,”FASEB Journal12:1063-1073 (1998).
Escribano et al., “cDNA from human ocular ciliary epithelium homologous to beta ig-h3 is preferentially expressed as an extracellular protein in the corneal epithelium,”J. Cell Physiol. 160:511-521 (1994).
Feng et al., “Cloning two isoforms of rat cyclooxygenase: Differential regulation of their expression,”Arch. Biochem. Biophys. 307:361-368 (1993).
FitzGerald et al., “COX-2 inhibitors and the cardiovascular system,”Clin. Exp. Rheumatol. 19:S31-S36 (2001).
Funk et al., “Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment,”FASEB J. 5:2304-2312 (1991).
Gierse et al, “A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors,”J. Biol. Chem. 271:15810-15814 (1996).
Hennan et al., “Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries,”Circulation104:820-825 (2001).
Hla, “Molecular characterization of the 5.2 KB isoform of the human cyclooxygenase-1 transcript,”Prostaglandins51:81-85 (1996).
Jones, “Practical COX-1 and COX-2 pharmacology: What's it all about?” 1-5. www.vetmedpub.com/cp/pdf/symposium
ov—1.pdf.
Kitzler et al., “Analysis and quantitation of splicing variants of the TPA-inducible PGHS-1 mRNA in rat tracheal epithelial cells,”Arch. Biochem. Biophys. 316:856-863 (1995).
Marnett et al., “Arachidonic acid oxygenation by COX-1 and COX-2: Mechanisms of catalysis and inhibition,”J. Biol. Chem. 274:22903-22906 (1999).
Marnett et al., “Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom,”Mol. Pharmacol. 26:328-335 (1984).
Matsuo and Cynader, “The EP2 receptor is the predominant prostanoid receptor in the human ciliary muscle,”Br. J. Ophthalmol. 77:110-114 (1993).
Merlie et al., “Isolation and characterization of the complementary DNA for sheep seminal vesical prostaglandin endoperoxide synthase (cyclooxygenase),”J. Biol. Chem. 263:3550-3553 (1988).
Neddleman et al., “Arachidonic acid metabolism,”Annu. Rev. Biochem. 55:69-102 (1986).
Olichon et al., “Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis,”J. Biol. Chem. 278:7743-7746 (2003).
Palmer and Henrich, “Clinical acute renal failure with nonsteroidal anti-inflammatory drugs,”Semin. Nephrol. 15:214-227 (1995).
Rowlinson et al., “The binding of arachidonic acid in the cyclooxygenase active site of mouse prostaglandin endoperoxide synthase-2 (COX-2). A putative L-shaped binding conformation utilizing the top channel region,”J. Biol. Chem. 274:23305-23310 (1999).
Schafer, “Effects of nonsteroidal anti-inflammatory drugs on platelet function and systemic hemostasis,”J. Clin. Pharmacol. 35:209-219 (1995).
Scott et al., “Characterization of the human prostaglandin H synthase 1 gene (PTGS1): Exclusion by genetic linkage analysis as a second modifier gene in familial thrombosis,”Blood Coagulation and Fibrinolysis13:519-531 (2002).
Silverstein et al., “Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The Class Study: A randomized controlled trial,”JAMA284:1247-1255 (2000).
Trevethick et al., “Non-steroid anti-inflammatory drug-induced gastric damage in experimental animals: Underlying pathological mechanisms,”Gen. Pharmacol. 26:1455-1459 (1995).
Van Haeringen et al., “Constitutive cyclooxygenase-1 and induced cyclooxygenase-2 in isolated human iris inhibited by S(+) flurbiprofen,”J. Ocul. Pharmacol. Ther. 16:353-361 (2000).
Vogiagis et al., “Cyclooxygenase-1 and an alternatively spliced mRNA in the rat stomach: Effects of aging and ulcers,”Am. J. Physiol. Gastrointest. Liver Physiol. 278:G820-G827 (2000).
Vogiagis et al., “Rat colorectal tumours treated with a range of non-steroidal anti-imflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels,”Carcinogenesis22:869-874 (2001).
Wallace, “Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years,”Gastroenterology112:1000-1016 (1997).
Wentzel et al., “Transcription of prostanoid receptor genes and cyclooxygenase enzyme genes in cultivated human iridial melanocytes from eyes of different colours,”Pigment Cell Res. 16:43-49 (2003).
Xie et al., “Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing,”Proc. Natl. Acad. Sci. USA88: 2692-2696 (1991).
Yokoyama and Tanabe, “Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme,”Biochem. Biophys. Res. Commun. 165:888-894 (1989).
Zambraski, The effects of nonsteroidal anti-inflammatory drugs on renal function: Experimental studies in animals,Semin. Nephrol. 15:205-213 (1995).
Genban
Liang Yanbin
Woodward David F.
Allergan Inc.
Chowdhury Iqbal
German Joel B.
Stathakis Dean G.
Voet Martin A.
LandOfFree
Human COX-1 alternatively spliced variants and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human COX-1 alternatively spliced variants and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human COX-1 alternatively spliced variants and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3798494